Trade SGMT stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Sagimet Biosciences Inc. Series A (SGMT) is trading at US$8.90, down 0.18% today as of Oct 9, 12:31 EDT. The company has a market capitalisation of US$637.13M. Over the past 52 weeks, SGMT has traded between US$4.50 and US$11.45. On Syfe you can trade SGMT with $0 commission and add it to your watchlist.
| Previous close | US$8.92 |
|---|---|
| Market cap | US$637.13M |
| 52-week range | US$4.50 – US$11.45 |
| Volume | 1.23M |
| Exchange | US |
Sagimet Biosciences Inc. Series A
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Year: 2023
Sagimet Biosciences Inc. Series A (SGMT) stock is trading at US$8.90, -0.18% from the previous close of US$8.92.
The market cap for Sagimet Biosciences Inc. Series A (SGMT) stock is approximately US$637.13M.
The 52-week high for Sagimet Biosciences Inc. Series A (SGMT) stock is US$11.45.
The 52-week low for Sagimet Biosciences Inc. Series A (SGMT) stock is US$4.50.
Sagimet Biosciences Inc. Series A (SGMT) does not currently pay a dividend.
Stay on top of SGMT
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
